AR042362A1 - Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen - Google Patents
Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR042362A1 AR042362A1 ARP030104562A ARP030104562A AR042362A1 AR 042362 A1 AR042362 A1 AR 042362A1 AR P030104562 A ARP030104562 A AR P030104562A AR P030104562 A ARP030104562 A AR P030104562A AR 042362 A1 AR042362 A1 AR 042362A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- pharmaceutical compositions
- compositions containing
- obtaining
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un proceso para su obtención, composiciones farmacéuticas que los contienen y su utilización como inhibidores selectivos de la monoamina-oxidasa B. Reivindicación 1: Un compuesto de la fórmula (1), en la que: R1 es -(CH2)n-CO-NR5R6; -(CH2)n-COOR7; -(CH2)n-NR5R6; -(CH2)n-CN; -(CH2)n-OR8; fenilo, que está sin sustituir o lleva de uno a tres sustituyentes elegidos entre halógeno y fluoralquilo C1-6; R2 es hidrógeno, halógeno o alquilo C1-6; R3 es hidrógeno, alquilo C1-6, cicloalquilo C3-6 o bencilo; R4 es halógeno, fluoralquilo C1-6, ciano, alcoxi C1-6 o fluoralcoxi C1-6; R5 y R6 con independencia entre sí son hidrógeno o alquilo C1-6; R7 es hidrógeno o alquilo C1-6; R8 es hidrógeno o alquilo C1-6; m es 1, 2, ó 3; y n es 0, 1, ó 2; y las sales farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02027700 | 2002-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042362A1 true AR042362A1 (es) | 2005-06-15 |
Family
ID=32524001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104562A AR042362A1 (es) | 2002-12-13 | 2003-12-11 | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7087612B2 (es) |
| EP (1) | EP1572666B1 (es) |
| JP (1) | JP4384053B2 (es) |
| KR (1) | KR100707532B1 (es) |
| CN (1) | CN100418954C (es) |
| AR (1) | AR042362A1 (es) |
| AT (1) | ATE335729T1 (es) |
| AU (1) | AU2003293798B8 (es) |
| BR (1) | BR0317282A (es) |
| CA (1) | CA2509633A1 (es) |
| CL (1) | CL2003002565A1 (es) |
| DE (1) | DE60307512T2 (es) |
| ES (1) | ES2270154T3 (es) |
| GT (1) | GT200300284A (es) |
| MX (1) | MXPA05006124A (es) |
| MY (1) | MY141743A (es) |
| PA (1) | PA8591901A1 (es) |
| PE (1) | PE20040911A1 (es) |
| PL (1) | PL377474A1 (es) |
| RU (1) | RU2340604C2 (es) |
| TW (1) | TW200424180A (es) |
| UY (1) | UY28120A1 (es) |
| WO (1) | WO2004054985A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006045096A2 (en) | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
| EP2281556A1 (en) | 2005-02-25 | 2011-02-09 | F. Hoffmann-La Roche AG | Tablets with improved drugs substance dispersibility |
| US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| GB0525068D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| JP4876690B2 (ja) * | 2006-04-21 | 2012-02-15 | 三菱瓦斯化学株式会社 | キナゾリン−４−オン誘導体の製造法 |
| JPWO2008087736A1 (ja) * | 2007-01-19 | 2010-05-06 | 宇部興産株式会社 | アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法 |
| EP2118074B1 (en) | 2007-02-01 | 2014-01-22 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| SI2346837T1 (sl) | 2008-06-26 | 2015-05-29 | Resverlogix Corporation | Postopki pripravljanja kinazolinonskih derivatov |
| US8952021B2 (en) | 2009-01-08 | 2015-02-10 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| WO2010106436A2 (en) | 2009-03-18 | 2010-09-23 | Resverlogix Corp. | Novel anti-inflammatory agents |
| CA2759241C (en) | 2009-04-22 | 2018-03-27 | Resverlogix Corp. | Novel anti-inflammatory agents |
| WO2013064900A1 (en) | 2011-11-01 | 2013-05-10 | Resverlogix Corp. | Oral immediate release formulations for substituted quinazolinones |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
| CN106146410B (zh) * | 2015-04-03 | 2018-10-12 | 中南大学 | 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途 |
| CN108191667B (zh) * | 2018-01-04 | 2021-03-26 | 利尔化学股份有限公司 | 2-硝基-4-三氟甲基苯甲酸甲酯的制备方法 |
| CN109553534A (zh) * | 2018-11-27 | 2019-04-02 | 常州大学 | 一种2-硝基-4-甲氧基苯甲酸的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6136273A (ja) * | 1984-07-26 | 1986-02-20 | Mitsubishi Yuka Yakuhin Kk | ２−フエニルアルキル−４（３ｈ）−キナゾリノン誘導体 |
| US5679715A (en) | 1995-06-07 | 1997-10-21 | Harris; Richard Y. | Method for treating multiple sclerosis |
| US5783577A (en) * | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
| AU709323B2 (en) | 1996-03-15 | 1999-08-26 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neuropathy by administering selegiline |
| DE69838172T2 (de) * | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| US6890930B1 (en) * | 1999-09-28 | 2005-05-10 | 3-Dimensional Pharmaceuticals, Inc. | Quinazolinones |
| WO2001034172A2 (en) | 1999-11-05 | 2001-05-17 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
-
2003
- 2003-12-08 DE DE60307512T patent/DE60307512T2/de not_active Expired - Lifetime
- 2003-12-08 RU RU2005121908/04A patent/RU2340604C2/ru not_active IP Right Cessation
- 2003-12-08 ES ES03789170T patent/ES2270154T3/es not_active Expired - Lifetime
- 2003-12-08 CA CA002509633A patent/CA2509633A1/en not_active Abandoned
- 2003-12-08 WO PCT/EP2003/013888 patent/WO2004054985A1/en active IP Right Grant
- 2003-12-08 CN CNB2003801052982A patent/CN100418954C/zh not_active Expired - Fee Related
- 2003-12-08 KR KR1020057010696A patent/KR100707532B1/ko not_active IP Right Cessation
- 2003-12-08 MX MXPA05006124A patent/MXPA05006124A/es active IP Right Grant
- 2003-12-08 AT AT03789170T patent/ATE335729T1/de not_active IP Right Cessation
- 2003-12-08 JP JP2004559781A patent/JP4384053B2/ja not_active Expired - Lifetime
- 2003-12-08 AU AU2003293798A patent/AU2003293798B8/en not_active Ceased
- 2003-12-08 EP EP03789170A patent/EP1572666B1/en not_active Expired - Lifetime
- 2003-12-08 PL PL377474A patent/PL377474A1/pl not_active Application Discontinuation
- 2003-12-08 BR BR0317282-1A patent/BR0317282A/pt not_active IP Right Cessation
- 2003-12-09 TW TW092134699A patent/TW200424180A/zh unknown
- 2003-12-10 CL CL200302565A patent/CL2003002565A1/es unknown
- 2003-12-10 PE PE2003001256A patent/PE20040911A1/es not_active Application Discontinuation
- 2003-12-10 PA PA20038591901A patent/PA8591901A1/es unknown
- 2003-12-11 GT GT200300284A patent/GT200300284A/es unknown
- 2003-12-11 AR ARP030104562A patent/AR042362A1/es unknown
- 2003-12-11 UY UY28120A patent/UY28120A1/es not_active Application Discontinuation
- 2003-12-12 MY MYPI20034764A patent/MY141743A/en unknown
- 2003-12-13 US US10/734,949 patent/US7087612B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PE20040911A1 (es) | 2004-12-11 |
| DE60307512D1 (de) | 2006-09-21 |
| AU2003293798B2 (en) | 2009-01-15 |
| US20040142951A1 (en) | 2004-07-22 |
| CN1720237A (zh) | 2006-01-11 |
| JP4384053B2 (ja) | 2009-12-16 |
| ES2270154T3 (es) | 2007-04-01 |
| EP1572666A1 (en) | 2005-09-14 |
| AU2003293798A1 (en) | 2004-07-09 |
| UY28120A1 (es) | 2004-06-30 |
| CN100418954C (zh) | 2008-09-17 |
| MY141743A (en) | 2010-06-30 |
| RU2340604C2 (ru) | 2008-12-10 |
| EP1572666B1 (en) | 2006-08-09 |
| AU2003293798B8 (en) | 2009-02-12 |
| RU2005121908A (ru) | 2006-01-27 |
| ATE335729T1 (de) | 2006-09-15 |
| KR20050085587A (ko) | 2005-08-29 |
| CA2509633A1 (en) | 2004-07-01 |
| CL2003002565A1 (es) | 2005-01-07 |
| KR100707532B1 (ko) | 2007-04-12 |
| MXPA05006124A (es) | 2005-08-16 |
| BR0317282A (pt) | 2005-11-08 |
| DE60307512T2 (de) | 2007-02-08 |
| GT200300284A (es) | 2004-07-14 |
| TW200424180A (en) | 2004-11-16 |
| US7087612B2 (en) | 2006-08-08 |
| WO2004054985A1 (en) | 2004-07-01 |
| JP2006513177A (ja) | 2006-04-20 |
| PA8591901A1 (es) | 2004-11-26 |
| PL377474A1 (pl) | 2006-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042362A1 (es) | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen | |
| AR052866A1 (es) | Fenil-metanonas monociclicas sustituidas | |
| AR039868A1 (es) | Inhibidores selectivos de la enzima kalikreina plasmatica | |
| PE20050676A1 (es) | Quinolinas referidas a enfermedades cardiovasculares | |
| AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| NO20052469L (no) | Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2. | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| NO20052976L (no) | Fosfodiesterase-4-inhibitorer. | |
| AR074817A1 (es) | Dihidropiridona-amidas como moduladores de p2x7 | |
| AR038562A1 (es) | 2-amino-4-biciclilamino-6h-1,3,5,-triazinas,procedimiento para su preparacion y su empleo como herbicidas y reguladores de crecimiento de plantas | |
| AR041299A1 (es) | Derivados de pirrolidona como inhibidores de maob | |
| AR044400A1 (es) | Procesos para la preparacion de derivados de pirimidina | |
| PE20060583A1 (es) | Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas | |
| UY27716A1 (es) | Derivados de nitrosodifenilamina y composiciones farmacéuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologías que se caracterizan por estrés oxidativo. | |
| NO331165B1 (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter | |
| UY27803A1 (es) | Derivados de benzoxazina y usos de los mismos. | |
| AR033879A1 (es) | Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto | |
| AR050266A1 (es) | Derivados de bencil-triazolona como inhibidores no nucleosidos de transcriptasa inversa | |
| AR039651A1 (es) | Derivados de isoquinolina | |
| CO5630005A2 (es) | Triazolopirimidinas sustituidas, procedimientos para su obtencion y el uso de las mismas para combatir hongos, asi como productos que las contienen | |
| AR043563A1 (es) | Inhibidores de catepsina s | |
| AR051392A1 (es) | Antagonistas no peptidicos de bradiquinina y composiciones farmaceuticas de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |